SCHEMBL17859653

SCHEMBL17859653

CCc1ccc(-c2ccccc2)cc1OC

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.49
KDM4E B2RXH2 4/20 0.49
MAPT P10636 3/20 0.49
ALDH1A1 P00352 3/20 0.49
GAA P10253 1/20 0.47
L3MBTL1 Q9Y468 3/20 0.44
LMNA P02545 2/20 0.44
HTT P42858 2/20 0.44
TDP1 Q9NUW8 2/20 0.44
KMT2A Q03164 1/20 0.44
PDCD1 Q15116 1/20 0.44
CD274 Q9NZQ7 1/20 0.44
HSD17B10 Q99714 2/20 0.44
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
CYP3A4 P08684 1/20 0.42
TSHR P16473 1/20 0.42
HTR2C P28335 1/20 0.42
EGFR P00533 1/20 0.42
PDE10A Q9Y233 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13614235 0.86 KDM4E (0.47) HPGDKDM4EMAPTALDH1A1GAA
SCHEMBL25147206 0.85 HPGD (0.46) HPGDKDM4EALDH1A1L3MBTL1LMNA
SCHEMBL26036254 0.85 HSD17B10 (0.44) HPGDMAPTALDH1A1LMNAHTT
SCHEMBL26036242 0.85 HSD17B10 (0.44) HPGDMAPTALDH1A1LMNAHTT
SCHEMBL6497164 0.84 PDCD1 (0.62) HPGDKDM4EMAPTALDH1A1GAA
SCHEMBL6488354 0.84 KDM4E (0.48) HPGDKDM4EMAPTALDH1A1GAA
SCHEMBL2568229 0.84 HTR2C (0.48) HPGDKDM4EMAPTALDH1A1GAA
SCHEMBL19760442 0.84 KDM4E (0.48) HPGDKDM4EMAPTALDH1A1GAA
SCHEMBL14318805 0.83 MEN1 (0.56) HPGDKDM4EMAPTALDH1A1GAA
SCHEMBL14318803 0.83 MEN1 (0.56) HPGDKDM4EMAPTALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230183286-A1 NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA NOVARTIS AG (CH) 2023-06-15 US disclosed
EP-3904366-A1 END CAPPED NUCLEIC ACID MOLECULES Novartis AG (CH) 2021-11-03 EP disclosed
US-20200190132-A1 NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2020-06-18 US disclosed
US-10676499-B2 3′ end caps, 5′ end caps and combinations thereof for therapeutic RNA NOVARTIS AG (CH) 2020-06-09 US disclosed
US-10246536-B2 Functionalized highly syndiotactic polystyrene and preparation method thereof CHANGCHUN INSTITUTE OF APPLIED CHEMISTRY CHINESE ACADEMY OF SCIENCES (CN) 2019-04-02 US disclosed
US-20170335036-A1 FUNCTIONALIZED HIGHLY SYNDIOTACTIC POLYSTYRENE AND PREPARATION METHOD THEREOF CHANGCHUN INSTITUTE OF APPLIED CHEMISTRY CHINESE ACADEMY OF SCIENCES (CN) 2017-11-23 US disclosed
WO-2016098028-A1 END CAPPED NUCLEIC ACID MOLECULES NOVARTIS AG (CH) 2016-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230183286-A1 NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA RNGTT, NSUN2, NSUN3 HPGD 4849/4885KDM4E 1565/4885MAPT 2121/4885
US-20200190132-A1 NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA RNGTT, NSUN2, NSUN3 HPGD 4849/4885KDM4E 1565/4885MAPT 2121/4885
US-10676499-B2 3′ end caps, 5′ end caps and combinations thereof for therapeutic RNA RNGTT, NSUN3, NSUN2 HPGD 4835/4885KDM4E 1535/4885MAPT 1907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.